751 variety form audit through the next step of work enterprises should focus on.

On Friday, September 18th, the 2020 health-care directory adjustment made new progress, and after the completion of the corporate filing process, the National Health Insurance Administration made public the list of companies that had passed the formal review.
number of varieties adopted in the review of the type of declaration of chinese medicines included in the New Coronavirus Pneumonia Diagnosis and Treatment Programme (Trial 7th Edition), 11 in Western medicine and 1 in the National Basic Medicines Directory (2018 Edition) 11, of which 8 are Western medicines and 3 are included in the List of Clinically Urgently Needed Foreign New Drugs (First Batch), Clinically Urgently Needed Overseas New Drugs List (Second Batch), First Batch of Encouraged Imitation Drugs Catalog, First Encouraging Research and Development to Declare Children's Drugs List, or The third batch of drugs to encourage research and development to declare the list of children's drugs, and by August 17, 2020 approved by the State Drug Administration for the listing of 28 drugs are the second batch of Western medicines centralized procurement of selected drugs 3 are Western medicines January 1-2, 2015 Between August 17, 2020, 171 new generic drugs were approved for sale by the State Drug Administration, of which 154 were Western medicines and 17 were Chinese generic drugs between January 1, 2015 and August 17, 2020. According to the results of clinical trials to the State Drug Administration supplementary application and approval, adaptive disorders, functional treatment and other major changes in the drug 10, of which 9 Western medicine, Chinese medicine 1 before December 31, 2019, into 5 (including) more than the latest provincial version of the basic medical insurance drug catalog of drugs.
, the main active ingredients were included in the "first batch of national key monitoring of rational drug use drugs catalogue (chemical drugs and biological products)" except 493, of which 338 Western medicine, 155 Chinese medicine within the validity period of the agreement, and In accordance with the agreement to redefine the payment criteria of the negotiation of 15 drugs, all Western medicine is within the validity period of the agreement, approved by the State Drug Administration, adaptation or functional treatment of major changes in the negotiation of 8 drugs, of which 1 Chinese traditional medicine a total of 751 this list means? Does the list mean that there is no objection during the publicity period, these drugs can enter the bidding or negotiation process? It should be noted that this publicity is the "2020 National Health Insurance Drug Catalog adjustment through the form of examination of the list of declared drugs", the small editor believes that the formal review through only the enterprise declaration of information and product attributes, such as the audit, that meets the declaration conditions, equivalent to qualification audit, this step for enterprises, is only the beginning of this year's medical insurance catalog adjustment work.
's the next step? According to the Interim Measures for the Administration of Basic Medical Insurance Drugs issued by the State Health Insurance Administration on July 31st, and the 2020 National Health Insurance Drug Catalog Adjustment Work Programme issued on August 17th, after the public announcement, the next step will be to establish a database of reviewed drugs in the light of the enterprise's declaration, which will be reviewed by the evaluation experts, thus forming a list of recommendations for the addition of drugs, direct transfer, transfer, adjustment of the scope of payment and other four aspects.
this list is the only one that will be adjusted for the 2020 health-care catalog.
in terms of progress and plans, the list may be released in mid-to-late October.
According to the relevant documents, the catalog adjustment of the next workflow is as follows: the "bid" and "negotiation" of the above-mentioned quasi-list after the completion of publicity, measurement experts will be through the fund measurement, pharmaceutical economics and other methods of the relevant enterprises to provide a follow-up material assessment, to provide a basis for the next work.
according to the rules, in addition to the second batch of national varieties, non-exclusive varieties will enter the bidding stage, and exclusive varieties into the negotiation process, all newly incorporated varieties will complete the determination of health insurance payment standards.
non-exclusive varieties of bidding link, is the new measures of the health insurance catalog adjustment, the previous adjustment work is not involved, the specific rules and procedures are not clear.
for the exclusive variety of countries, and one pilot and three groups of negotiations have been completed.
In terms of previous years' work, the general process is as follows: 1. Experts determine the expected price of varieties and their health insurance: clinical, pharmacological, pharmaceutical economics, medical insurance and other experts to conduct multiple rounds of evaluation; Five people; the expected price paid for health insurance is placed in an envelope, the negotiation begins with the negotiator's knowledge; each item takes about 30 minutes to negotiate; the company can make two rounds of offers to terminate the negotiations if the price is more than 15% of the expected price paid by medicare; and in the end, the price acceptable to both parties is less than or equal to the expected price of the health insurance.
. On-site signature confirmation, according to the outcome of the negotiations, signed a formal agreement with the enterprise.
This year's medical insurance catalog adjustment rules are much different than in the past, how to determine the standard of payment for health insurance, but also to see the next work arrangements, especially the bidding part, the relevant enterprises should always pay attention to the policy dynamics, do a good job of relevant strategic adjustment.
.